Subtype
Malignant Retinal Neoplasm
CI-CAN-00001173Explore in graph →
15 active trials1 approved drugs2 evidence items
- NCIt
- C3216
Loading cancer entity…
Subtype
CI-CAN-00001173Explore in graph →
Clinical trials
111 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (16)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01109394 | Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies | recruiting | — | 6,035 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05504291 | A Study to Give Treatment Inside the Eye to Treat Retinoblastoma | recruiting | Phase 2 | 26 | Children's Oncology GroupNETWORK | 3 | Aug 25, 2026 | clinicaltrials |
| NCT05650749 | GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma(GPC2) | enrolling by invitation | Phase 1 | 45 | Stephan Grupp MD PhDOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT03655223 | Early Check: Expanded Screening in Newborns | active not recruiting | — | 30,000 | RTI InternationalOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT01783535 | Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma | active not recruiting | Phase 2 | 174 | St. Jude Children's Research HospitalOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT03050268 | Familial Investigations of Childhood Cancer Predisposition(SJFAMILY) | recruiting | — | 1,500 | St. Jude Children's Research HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT03546387 | Determining Whether Multiple Anesthesia Exposures Affect Cognitive Function for Retinoblastoma Patients | recruiting | — | 75 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT06679634 | Retinoblastoma Phase II Expanded Access Clinical Trial | recruiting | Phase 2 | 30 | Targeted Therapy Technologies, LLCINDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT04483778 | B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | active not recruiting | Phase 1 | 68 | Seattle Children's HospitalOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT04959097 | Retinoblastoma Patient Clinical Database and Tissue Repository | recruiting | — | 800 | Children's Hospital Los AngelesOTHER | 2 | Apr 22, 2026 | clinicaltrials |
| NCT07530458 | Retinoblastoma Consolidation in Egyptians | not yet recruiting | — | 150 | Assiut UniversityOTHER | 0 | Apr 15, 2026 | clinicaltrials |
| NCT06725173 | Detailed Phenotypic and Genotype Study to Correlate RB1 Mutations Relating to Primary Ocular Tumors and Secondary Extra-ocular Metastasis. | recruiting | — | 100 | University of WashingtonOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04425434 | Therapeutic Recommendations For The Treatment Of Children With A Retinoblastoma(GFARB12019) | recruiting | — | 3,000 | French Africa Pediatric Oncology GroupOTHER | 6 | Mar 2, 2026 | clinicaltrials |
| NCT00639301 | Retinoblastoma Survivor Study: Assessment of General Health and Quality of Life | active not recruiting | — | 473 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT02870907 | Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009)(RB SFCE 09) | active not recruiting | Phase 2 | 195 | Institut CurieOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT03267459 | Can Pretreatment MRI be Used to Predict Intra-arterial Chemotherapy Response in Retinoblastoma?(PREDIR) | recruiting | — | 60 | Fondation Ophtalmologique Adolphe de RothschildNETWORK | 1 | Jan 5, 2026 | clinicaltrials |
| NCT06227962 | Cognitive Functioning and Health Related Quality of Life in Retinoblastoma Survivors(RbNeuroQoL) | enrolling by invitation | — | 240 | Amsterdam University Medical CenterOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT04681417 | Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome(RETINO 2018) | recruiting | Phase 2 / Phase 3 | 225 | Institut CurieOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT02866136 | Conservative Treatments of Retinoblastoma(RETINO2011) | active not recruiting | Phase 2 | 133 | Institut CurieOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT03618381 | EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | active not recruiting | Phase 1 | 44 | Seattle Children's HospitalOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT03932786 | Studying Health Outcomes After Treatment in Patients With Retinoblastoma(RIVERBOAT) | recruiting | — | 900 | Vanderbilt-Ingram Cancer CenterOTHER | 2 | Sep 19, 2025 | clinicaltrials |
| NCT03026998 | MRI Screening of Second Primary Cancer Occurring Within Radiation Fields After Treatment by External Beam Radiation Therapy for Hereditary Retinoblastoma (DepiSCARRH)(DepiSCARRH) | active not recruiting | N/A | 88 | Institut CurieOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT06424301 | Targeting NUDT21 siRNA Drugs for Patients With Refractory Retinoblastoma | recruiting | Early Phase 1 | 2 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT06972602 | High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous Seed | recruiting | Early Phase 1 | 10 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT04903678 | Intrathecal Chemotherapy for Central Nervous System Metastasis in Retinoblastoma | recruiting | N/A | 18 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06367530 | Trilateral Retinoblastoma: Incidence and Outcomes(GS-TRIO) | recruiting | — | 4,351 | Amsterdam UMC, location VUmcOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT05080010 | Adjuvant Chemotherapy for High-risk Postenucleation Retinoblastoma | recruiting | Phase 3 | 500 | Sun Yat-sen UniversityOTHER | 1 | Oct 15, 2021 | clinicaltrials |
| NCT04799002 | Topotecan and Melphalan for Retinoblastoma | recruiting | Phase 3 | 50 | Sun Yat-sen UniversityOTHER | 1 | Mar 16, 2021 | clinicaltrials |
Data updated yesterdaySource updated Sep 28, 2026source: clinicaltrials